Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abingdon Life Sciences has signed an agreement with Stason Pharmaceuticals to provide clinical and regulatory support for Stason's drug development programs.
Subscribe to our email newsletter
As part of the agreement, Abingdon will provide clinical and regulatory services for Stason’s pipeline of potential drug candidates and devices in the areas of cancer and inflammation.
Richard Lebovitz, CEO of Abingdon, said: “We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing.”